Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts

Autoimmunity Reviews

Volumn 16, Issue 8, 2017, Pages 826-832

  Ruiz Irastorza, Guillermo ^a   Ugarte, Amaia ^a   Saint Pastou Terrier, Cecile ^b   Lazaro, Estibaliz ^b,c   Iza, Amalur ^a   Couzi, Lionel ^c,d   Saenz, Ramon ^a   Richez, Christophe ^c,d   Porta, Sabrina ^a,e   Blanco, Patrick ^c,d  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d HÔPITAL PELLEGRIN   (France)

^e HOSPITAL RAMOS MEJÍA   (Argentina)

Author keywords

Cyclophosphamide; Glucocorticoids; Hydroxychloroquine; Lupus nephritis; Methyl prednisolone; Prednisone; Proteinuria; Side effects; Systemic lupus erythematosus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCIUM; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; VITAMIN D; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADJUVANT THERAPY; ADULT; AVASCULAR NECROSIS; CATARACT; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; LOW DRUG DOSE; LUNG HEMORRHAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOON FACE; OBESITY; PRACTICE GUIDELINE; PROTEINURIA; RELAPSE; REMISSION; REPEATED DRUG DOSE; RETREATMENT; REVIEW; SPINE FRACTURE; STRIA; SURVIVAL; TREATMENT DURATION; COMBINATION DRUG THERAPY; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; REMISSION INDUCTION; YOUNG ADULT;

EID: 85020100924     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.05.017     Document Type: Review

References (31)

1. Mok, C.C., Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol 12 (2016), 221–234.
2. Hahn, B.H., McMahon, M.A., Wilkinson, A., Wallace, W.D., Daikh, D.I., Fitzgerald, J.D., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 64 (2012), 797–808.
3. Bertsias, G.K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I.M., Berden, J.H.M., et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71 (2012), 1771–1782.
4. Ruiz-Irastorza, G., Espinosa, G., Frutos, M.A., Jimenez-Alonso, J., Praga, M., Pallarés, L., et al. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia 32 (2012), S1–S35.
5. KDIGO, Clinical practice guideline for glomerulonephritis. Kidney Int 2 (2012), 1–143.
6. Wilhelmus, S., Bajema, I.M., Bertsias, G.K., Boumpas, D.T., Gordon, C., Lightstone, L., et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant 31 (2016), 904–913.
7. Tektonidou, M.G., Dasgupta, A., Ward, M.M., Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68 (2016), 1432–1441.
8. Ruiz-Arruza, I., Ugarte, A., Cabezas-Rodriguez, I., Medina, J.-A., Moran, M.-A., Ruiz-Irastorza, G., Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 53 (2014), 1470–1476.
9. Zeher, M., Doria, A., Lan, J., Aroca, G., Jayne, D., Boletis, I., et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 20 (2011), 1484–1493.
10. Fischer-Betz, R., Chehab, G., Sander, O., Vordenbäumen, S., Voiculescu, A., Brinks, R., et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J Rheumatol 39 (2012), 2111–2117.
11. Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162 (2015), 18–26.
12. Condon, M.B., Ashby, D., Pepper, R.J., Cook, H.T., Levy, J.B., Griffith, M., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72 (2013), 1280–1286.
13. Ruiz-Irastorza, G., Danza, A., Perales, I., Villar, I., Garcia, M., Delgado, S., et al. Prednisone in lupus nephritis: how much is enough?. Autoimmun Rev 13 (2014), 206–214.
14. Hochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 40, 1997, 1725.
15. Weening, J.J., D'Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65 (2004), 521–530.
16. Houssiau, F.A., Vasconcelos, C., D'Cruz, D.P., Sebastiani, G.D., Garrido Ed E de, R., Danieli, M.G., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46 (2002), 2121–2131.
17. Salesi, M., Karimifar, M., Farajzadegan, Z., Esalatmanesh, K., Khosravi, S., Fallahi, P., et al. The protein-creatinine ratio in spot morning urine samples and 24-h urinary protein excretion in patients with systemic lupus erythematosus. Rheumatol Int 29 (2009), 503–507.
18. Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N., Roth, D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130 (1999), 461–470.
19. Tamirou, F., Lauwerys, B.R., Dall'era, M., Mackay, M., Rovin, B., Cervera, R., et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med, 2, 2015, e000123.
20. Mok, C.C., Ying, K.Y., Yim, C.W., Siu, Y.P., Tong, K.H., To, C.H., et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis 75 (2016), 30–36.
21. Stahn, C., Buttgereit, F., Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 4 (2008), 525–533.
22. Buttgereit, F., Scheffold, A., Rapid glucocorticoid effects on immune cells. Steroids 67 (2002), 529–534.
23. Ruiz-Irastorza, G., Garcia, M., Espinosa, G., Caminal, L., Mitjavila, F., González-León, R., et al. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med, 3, 2016, e000153.
24. Tanaka, M., Yamada, S., Iwasaki, Y., Sugishita, T., Yonemoto, S., Tsukamoto, T., et al. Impact of obesity on IgA nephropathy: comparative ultrastructural study between obese and non-obese patients. Nephron Clin Pract 112 (2009), 71–78.
25. Mudge, S.J., Paizis, K., Auwardt, R.B., Levidiotis, V., Fraser, S.A., Power, D.A., Corticosteroids worsen proteinuria and increase intraglomerular signaling by NF-ĸB in a model of membranous glomerulonephritis. Nephron Exp Nephrol 116 (2010), e23–e31.
26. Kumagai, H., Hishida, A., Nagase, M., Honda, N., Mechanisms of steroid-enhanced proteinuria in nephrotic patients. Nihon Jinzo Gakkai Shi 29 (1987), 277–281.
27. Wetzels, J.F., Gerlag, P.G., Sluiter, H.E., Hoitsma, A.J., Koene, R.A., Prednisone-induced fluctuations of proteinuria in patients with a nephrotic syndrome. Nephron 44 (1986), 344–350.
28. Wetzels, J.F., Sluiter, H.E., Hoitsma, A.J., van Munster, P.J., Koene, R.A., Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney Int 33 (1988), 1169–1174.
29. Reichert, L.J., Koene, R.A., Wetzels, J.F., Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome. Nephrol Dial Transplant 14 (1999), 91–97.
30. Heymann, W., Grupe, W.E., Increase in proteinuria due to steroid medication in chronic renal disease. J Pediatr 74 (1969), 356–363.
31. Ruiz-Arruza, I., Barbosa, C., Ugarte, A., Ruiz-Irastorza, G., Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev 14 (2015), 875–879.